BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

784 related articles for article (PubMed ID: 16724649)

  • 21. Effect of oral pilocarpine on post-irradiation xerostomia in head and neck cancer patients: a single-center, single-blind clinical trial.
    Chitapanarux I; Kamnerdsupaphon P; Tharavichitkul E; Sumitsawan Y; Sittitrai P; Pattarasakulchai T; Lorvidhaya V; Sukthomya V; Pukanhaphan N; Traisatit P
    J Med Assoc Thai; 2008 Sep; 91(9):1410-5. PubMed ID: 18843872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms.
    Su CK; Mehta V; Ravikumar L; Shah R; Pinto H; Halpern J; Koong A; Goffinet D; Le QT
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):171-7. PubMed ID: 15337553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
    de Castro G; Federico MH
    Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional outcomes related to the prevention of radiation-induced xerostomia: oral pilocarpine versus submandibular salivary gland transfer.
    Rieger JM; Jha N; Lam Tang JA; Harris J; Seikaly H
    Head Neck; 2012 Feb; 34(2):168-74. PubMed ID: 21416547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using technology to decrease xerostomia for head and neck cancer patients treated with radiation therapy.
    Amosson CM; Teh BS; Mai WY; Woo SY; Chiu JK; Donovan DT; Parke R; Carpenter LS; Lu HH; Grant WH; Butler EB
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):71-9. PubMed ID: 12577249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer.
    Jellema AP; Slotman BJ; Doornaert P; Leemans CR; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):751-60. PubMed ID: 17560735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management.
    Chambers MS; Garden AS; Kies MS; Martin JW
    Head Neck; 2004 Sep; 26(9):796-807. PubMed ID: 15350026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.
    Langendijk JA; Doornaert P; Verdonck-de Leeuw IM; Leemans CR; Aaronson NK; Slotman BJ
    J Clin Oncol; 2008 Aug; 26(22):3770-6. PubMed ID: 18669465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized phase III prospective trial of bethanechol to prevent radiotherapy-induced salivary gland damage in patients with head and neck cancer.
    Jham BC; Teixeira IV; Aboud CG; Carvalho AL; Coelho Mde M; Freire AR
    Oral Oncol; 2007 Feb; 43(2):137-42. PubMed ID: 16798061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantifying radioxerostomia: salivary flow rate, examiner's score, and quality of life questionnaire.
    Al-Nawas B; Al-Nawas K; Kunkel M; Grötz KA
    Strahlenther Onkol; 2006 Jun; 182(6):336-41. PubMed ID: 16703289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
    Jabbari S; Kim HM; Feng M; Lin A; Tsien C; Elshaikh M; Terrel JE; Murdoch-Kinch C; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):725-31. PubMed ID: 16199308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salivary flow rates measured during radiation therapy in head and neck cancer patients: a pilot study assessing salivary sediment formation.
    Chambers MS; Tomsett KL; Artopoulou II; Garden AS; El-Naggar AK; Martin JW; Keene HJ
    J Prosthet Dent; 2008 Aug; 100(2):142-6. PubMed ID: 18672129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pilocarpine for radiation-induced xerostomia in head and neck cancer.
    Hawthorne M; Sullivan K
    Int J Palliat Nurs; 2000 May; 6(5):228-32. PubMed ID: 12419994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel dose constraint to reduce xerostomia in head-and-neck cancer patients treated with intensity-modulated radiotherapy.
    Strigari L; Benassi M; Arcangeli G; Bruzzaniti V; Giovinazzo G; Marucci L
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):269-76. PubMed ID: 20100642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.
    Blanco AI; Chao KS; El Naqa I; Franklin GE; Zakarian K; Vicic M; Deasy JO
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1055-69. PubMed ID: 15990009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer.
    Meirovitz A; Murdoch-Kinch CA; Schipper M; Pan C; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):445-53. PubMed ID: 16839705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis.
    Duncan GG; Epstein JB; Tu D; El Sayed S; Bezjak A; Ottaway J; Pater J;
    Head Neck; 2005 May; 27(5):421-8. PubMed ID: 15782422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials.
    Rieke JW; Hafermann MD; Johnson JT; LeVeque FG; Iwamoto R; Steiger BW; Muscoplat C; Gallagher SC
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):661-9. PubMed ID: 7852133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.